ValiRx Plc (AIM: VAL) has highlighted its indirect 5.55% shareholding in Ambrose Healthcare following the private pharmaceutical company’s agreement to acquire AM-Pharma for up to €161 million, drawing investor attention
Genflow Biosciences Trial Meets Primary Endpoint in Aged Beagles
Genflow Biosciences Ltd (LON: GENF) has reported that its SLAB clinical trial evaluating the company’s SIRT6 centenarian gene therapy in aged beagles has met its primary endpoint.
ValiRx Secures Second European Patent for Cytolytix Cancer-Killing Peptide
ValiRx PLC (AIM: VAL) has received notice that the European Patent Office intends to grant a second patent covering the cancer-killing peptide being developed by its majority-owned subsidiary Cytolytix.
Genflow Biosciences to Showcase Longevity Gene Therapy Data at Major Industry Summit
Genflow Biosciences plc (LON: GENF) has been invited to present results from its SLAB (Sarcopenia and Longevity in Aged Beagles) study at the Animal Longevity Summit 2026, a specialist conference
Positive dog gene therapy data lifts Genflow shares 15%
Genflow Biosciences PLC (LON: GENF) has reported encouraging preliminary interim results from its SLAB clinical trial assessing its SIRT6 gene therapy in aged dogs.
Genflow Biosciences Plc appointed Gad Berdugo as Independent Non-Executive Chairman
Genflow Biosciences Plc (LON: GENF) has appointed Gad Berdugo as Independent Non-Executive Chairman, a move intended to support the group’s next phase of corporate development and R&D expansion.
ValiRx plc (AIM: VAL) New Evaluation and Material Transfer Agreement
ValiRx plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women’s health and The Royal Institute for the Advancement of Learning/McGill University (“McGill”), a Canadian based
Genflow Biosciences PLC (LON: GENF) A Review of an Exciting 2025
Genflow Biosciences PLC (LON: GENF) said it made solid operational progress during 2025, advancing multiple programmes across aging, metabolic disease and gene therapy, while laying the groundwork for a more
Genflow Biosciences Plc (LON: GENF) Completion of Dosing Phase of Canine Gene Therapy
Genflow Completes Dosing Phase of Canine Gene Therapy Trial No Adverse Events Reported During Administration
Genflow Biosciences Plc (LON: GENF) to pitch longevity gene therapy at JPM 2026
Genflow to Attend the 44th Annual J.P. Morgan Healthcare Conference
Genflow Biosciences Shares Jump 25% on Positive Dog Aging Gene Therapy Results
Update on Animal Health Program
Genflow Biosciences (LON: GENF) Shares Jump 100% After Alternative Share Placement
Genflow Biosciences Raises £440,000 Through Alternative Share Placement.